Company intelligence / Profile preview

Liaoning Green Biological Pharmaceutical Group

Shenyang, Liaoning, Chinabloomberg.com ↗

Ownership: Private
Development stage: Commercial

Overview

Liaoning Green Biological Pharmaceutical Group develops small molecule drugs with a focus on urogenital diseases and related indications. Its lead asset, PE‑001, has reached Phase 2 clinical trials for premature ejaculation. Another candidate, MT‑1207, has been evaluated in early-stage clinical studies for hypertension to assess tolerability and pharmacokinetics. The company appears to have at least two active programs in its pipeline as of June 2025[1].

Therapeutic areas: CardiovascularNephrologyMen's Health
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

1 asset

MT-1207

Unknown

Partnerships

China Pharmaceutical University (originator organization for PE‑001)[1]

Beyond the preview

Go deeper on Liaoning Green Biological Pharmaceutical Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liaoning Green Biological Pharmaceutical Group.

Explore the full profile